We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00668382
Recruitment Status : Completed
First Posted : April 29, 2008
Results First Posted : November 26, 2012
Last Update Posted : May 15, 2013
Information provided by (Responsible Party):
Giles Whalen, University of Massachusetts, Worcester

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label)
Condition: Neoplasm Metastases
Intervention: Biological: Alpha-Gal Glycosphingolipid

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients recruited from medical and surgical oncology clinics with currently untreatable tumors from march 2007 through June 2011

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No assignment to separate arms, Patients had to be off any active treatment for their advanced tumors for at least 2 weeks before entry onto study and a month after. Two subjects withdrew after screening and consent because of stroke (1) and insurance refusal(1). Two patients dropped out in the first month due to treatment needs.

Reporting Groups
Alpha-Gal Glycosphingolipid Injection Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)

Participant Flow:   Overall Study
    Alpha-Gal Glycosphingolipid Injection
STARTED   11 [1] 
[1] beginning of trial

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Alpha-Gal Glycosphingolipid Injection Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)

Baseline Measures
   Alpha-Gal Glycosphingolipid Injection 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   7 
>=65 years   4 
[Units: Years]
Mean (Standard Deviation)
 60  (12.5) 
[Units: Participants]
Female   3 
Male   8 
Region of Enrollment 
[Units: Participants]
United States   11 

  Outcome Measures

1.  Primary:   Number of Subjects With Greater Than Grade 3 or 4 Toxicity   [ Time Frame: 1 month ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No allergic/immune toxicity. The single toxicity/AE was bacterial infection with UGI flora at injection site following EUS (endoscopic ultra-sound) guided injection of pancreatic cancer. Added injections covered with antibiotic prophylaxis.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Sheila Noone
Organization: UMass Medical Scool
phone: 508 856 5015
e-mail: Sheil.Noone@umasmed.edu

Publications of Results:

Responsible Party: Giles Whalen, University of Massachusetts, Worcester
ClinicalTrials.gov Identifier: NCT00668382     History of Changes
Other Study ID Numbers: UM200702
First Submitted: April 25, 2008
First Posted: April 29, 2008
Results First Submitted: October 25, 2012
Results First Posted: November 26, 2012
Last Update Posted: May 15, 2013